From medicine to markets: Long-term biotech investing

Biotech investing often hinges on understanding science, trials and patient outcomes. Dr. Judith Finegold is a physician-turned-equity analyst, and she explains how her clinical experience helps assess drug pipelines, clinical trials and long‑term risk in biotech investing — well beyond the headlines. #CapGroupGlobal Listen on Apple Podcasts: https://apple.co/4tgNL36 Listen on Spotify: https://bit.ly/41rQLhr 00:00 Introduction 00:31 What is your investment edge? 01:40 Do you ever miss being a doctor? 02:00 How do you translate your background into being an investor? 02:49 How does your background impact how you interact with management teams? 03:38 What do you look for in U.S. biotech companies that others don't? 05:22 Could Lp(a) be the GLP-1 five years from now? 06:14 Why are you so excited about small- and mid-cap biotech? 07:50 Are the small-cap and large-cap management teams very different? 09:08 How many meetings do you do, who's there and what are the conversations like? 09:58 Take us inside the format of your meetings — how does it work? 10:43 How do you partner with your non-U.S. focused colleague? 11:37 What are some lessons you've learned? 12:47 Are there one or two mentors who have helped you in your career? 13:51 Office treasure hunt 14:58 In addition to your role as an analyst, tell us about your role as a research director 15:55 What advice would you give someone who is an early career joiner? 17:10 Tell us about your personal life and interest in chickens, traveling and ballet 18:39 Obsessively grateful moment This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures: https://www.capitalgroup.com/global-d...